Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers

Nephrology ◽  
2013 ◽  
Vol 18 (7) ◽  
pp. 516-524 ◽  
Author(s):  
Sara E Ivory ◽  
David K Packham ◽  
Anne T Reutens ◽  
Rory Wolfe ◽  
Richard D Rohde ◽  
...  
Keyword(s):  
Renal Impairment ◽  
Angiotensin Receptor Blockers ◽  
Optimal Treatment ◽  
Diabetic Patients ◽  
Angiotensin Receptor ◽  
Type 2 Diabetic Patients ◽  
Receptor Blockers ◽  
Type 2 Diabetic

scholarly journals Arterial stiffness and renal impairment in non-proteinuric type 2 diabetic patients

2011 ◽  
Vol 3 (1) ◽  
pp. 86-91 ◽  
Author(s):  
Keiko Nakao ◽  
Takashi Uzu ◽  
Shin-ichi Araki ◽  
Shinji Kume ◽  
Naoko Deji ◽  
...  
Keyword(s):  
Arterial Stiffness ◽  
Renal Impairment ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Antihypertensive Drugs and Diabetic Retinopathy in Patients with Type 2 Diabetes

2015 ◽  
Vol 235 (2) ◽  
pp. 87-96
Author(s):  
Jen-Chieh Lin ◽  
Mei-Shu Lai
Keyword(s):  
Diabetic Retinopathy ◽  
Antihypertensive Drugs ◽  
Angiotensin Receptor Blockers ◽  
Incidence Rates ◽  
Diabetic Patients ◽  
Channel Blockers ◽  
Type 2 Diabetic Patients ◽  
Converting Enzyme Inhibitors ◽  
Type 2 Diabetic

Objective: To evaluate the association between the development of sight-threatening diabetic retinopathy (STDR) and antihypertensive drugs (AHDs) use among type 2 diabetic patients with concomitant hypertension. Methods: Type 2 diabetic patients aged 20-100 years who had at least one prescription for AHDs between 2000 and 2011 were identified from the Longitudinal Health Insurance Database (LHID) 2005. The incidence rates of STDR were followed and Cox proportional hazard models were used to analyze the risk associated with AHDs. Results: Users of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) were associated with a significantly higher risk than users of calcium channel blockers (CCBs), independent of baseline characteristics. After adjusting for time-varying use of concomitant medications for propensity score-matched or -unmatched cohorts, the results showed that patients receiving ACEIs/ARBs and CCBs were associated with a significantly greater risk compared with β-blocker users. Conclusions: Our study did not support a superiority of ACEIs/ARBs and CCBs over β-blockers for lowering the progression of diabetic retinopathy.

Carbamylation of LDL and its relationship with myeloperoxidase in Type 2 diabetes mellitus

2013 ◽  
Vol 126 (2) ◽  
pp. 175-181 ◽  
Author(s):  
Sammy W. M. Shiu ◽  
Su-Mei Xiao ◽  
Ying Wong ◽  
Wing-Sun Chow ◽  
Karen S. L. Lam ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Renal Impairment ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Independent Mechanism ◽  
Type 2 Diabetic

Protein carbamylation has been considered only quantitatively important in uraemia and carbamylated LDL is pro-atherogenic. We have shown that carbamylated LDL is increased in Type 2 diabetic patients without renal impairment. Carbamylation is mediated by a urea-independent mechanism via myeloperoxidase.

scholarly journals Preventing microalbuminuria with benazepril, valsartan, and benazepril–valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study

PLoS Medicine ◽  
2021 ◽  
Vol 18 (7) ◽  
pp. e1003691
Author(s):  
Piero Ruggenenti ◽  
Monica Cortinovis ◽  
Aneliya Parvanova ◽  
Matias Trillini ◽  
Ilian P. Iliev ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Angiotensin Receptor Blockers ◽  
Combined Therapy ◽  
Accelerated Failure Time Model ◽  
Diabetic Patients ◽  
Open Label ◽  
Type 2 Diabetic Patients ◽  
Link Type ◽  
Type 2 Diabetic

Background Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) prevent microalbuminuria in normoalbuminuric type 2 diabetic patients. We assessed whether combined therapy with the 2 medications may prevent microalbuminuria better than ACE inhibitor or ARB monotherapy. Methods and findings VARIETY was a prospective, randomized, open-label, blinded endpoint (PROBE) trial evaluating whether, at similar blood pressure (BP) control, combined therapy with benazepril (10 mg/day) and valsartan (160 mg/day) would prevent microalbuminuria more effectively than benazepril (20 mg/day) or valsartan (320 mg/day) monotherapy in 612 type 2 diabetic patients with high-normal albuminuria included between July 2007 and April 2013 by the Istituto di Ricerche Farmacologiche Mario Negri IRCCS and 8 diabetology or nephrology units in Italy. Time to progression to microalbuminuria was the primary outcome. Analyses were intention to treat. Baseline characteristics were similar among groups. During a median [interquartile range, IQR] follow-up of 66 [42 to 83] months, 53 patients (27.0%) on combination therapy, 57 (28.1%) on benazepril, and 64 (31.8%) on valsartan reached microalbuminuria. Using an accelerated failure time model, the estimated acceleration factors were 1.410 (95% CI: 0.806 to 2.467, P = 0.229) for benazepril compared to combination therapy, 0.799 (95% CI: 0.422 to 1.514, P = 0.492) for benazepril compared to valsartan, and 1.665 (95% CI: 1.007 to 2.746, P = 0.047) for valsartan compared to combination therapy. Between-group differences in estimated acceleration factors were nonsignificant after adjustment for predefined confounders. BP control was similar across groups. All treatments were safe and tolerated well, with a slight excess of hyperkalemia and hypotension in the combination therapy group. The main study limitation was the lower than expected albuminuria at inclusion. Conclusions Risk/benefit profile of study treatments was similar. Dual renin–angiotensin system (RAS) blockade is not recommended as compared to benazepril or valsartan monotherapy for prevention of microalbuminuria in normoalbuminuric type 2 diabetic patients. Trial registration EudraCT 2006-005954-62; ClinicalTrials.gov NCT00503152.

scholarly journals Incidence and risk of anemia in type-2 diabetic patients in the absence of renal impairment

Health ◽  
2012 ◽  
Vol 04 (06) ◽  
pp. 304-308 ◽  
Author(s):  
Babatunde Ishola Adejumo ◽  
Uchechukwu Dimkpa ◽  
Chinwe Obianuju Ewenighi ◽  
Abduffatah Adekunle Onifade ◽  
Azukaego Thomas Mokogwu ◽  
...  
Keyword(s):  
Renal Impairment ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document